[Paradigm shift in the treatment of atrial fibrillation. The importance of risk factor management]

Stefania Aur1, Patrizio Pascale1

  • 1Service de cardiologie, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|June 23, 2017
PubMed

Insights

Rising atrial fibrillation (AF) prevalence necessitates treating modifiable risk factors like obesity and hypertension. Addressing these comorbidities alongside standard treatments can significantly reduce AF burden and recurrence rates.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) prevalence is increasing globally.
  • AF is linked to modifiable risk factors including obesity, obstructive sleep apnea, hypertension, and sedentary lifestyles.

Purpose of the Study:

  • To emphasize the need for a paradigm shift in AF management.
  • To highlight the importance of treating comorbidities to reduce AF burden and recurrence.

Main Methods:

  • Review of existing studies correlating AF with modifiable risk factors.
  • Analysis of the impact of treating comorbidities on AF outcomes.

Main Results:

  • Treatment of associated risk factors can significantly decrease AF prevalence and recurrence post-intervention.
  • Current AF management strategies focusing solely on ablation or medication are insufficient.

Conclusions:

  • A comprehensive approach combining AF-specific treatments with aggressive management of risk factors is crucial.
  • This integrated strategy is essential for improving long-term success rates in AF management, similar to cardiovascular disease treatment protocols.

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
545
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
420
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
365
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
450